Systems genetics identifies miRNA-mediated regulation of host response in COVID-19.

BACKGROUND: Individuals infected with SARS-CoV-2 vary greatly in their disease severity, ranging from asymptomatic infection to severe disease. The regulation of gene expression is an important mechanism in the host immune response and can modulate the outcome of the disease. miRNAs play important roles in post-transcriptional regulation with consequences on downstream molecular and cellular host immune response processes. The nature and magnitude of miRNA perturbations associated with blood phenotypes and intensive care unit (ICU) admission in COVID-19 are poorly understood. RESULTS: We combined multi-omics profiling-genotyping, miRNA and RNA expression, measured at the time of hospital admission soon after the onset of COVID-19 symptoms-with phenotypes from electronic health records to understand how miRNA expression contributes to variation in disease severity in a diverse cohort of 259 unvaccinated patients in Abu Dhabi, United Arab Emirates. We analyzed 62 clinical variables and expression levels of 632 miRNAs measured at admission and identified 97 miRNAs associated with 8 blood phenotypes significantly associated with later ICU admission. Integrative miRNA-mRNA cross-correlation analysis identified multiple miRNA-mRNA-blood endophenotype associations and revealed the effect of miR-143-3p on neutrophil count mediated by the expression of its target gene BCL2. We report 168 significant cis-miRNA expression quantitative trait loci, 57 of which implicate miRNAs associated with either ICU admission or a blood endophenotype. CONCLUSIONS: This systems genetics study has given rise to a genomic picture of the architecture of whole blood miRNAs in unvaccinated COVID-19 patients and pinpoints post-transcriptional regulation as a potential mechanism that impacts blood traits underlying COVID-19 severity. The results also highlight the impact of host genetic regulatory control of miRNA expression in early stages of COVID-19 disease.

Results of the interventional treatment for acute myocardial infarction (year 2010-2014) / Шинэ санаа Шинэ нээлт

The Cardiovascular disease is leading the cause of mortality and morbidity and constantly increasingevery year for past decades. World wide 32 million people gets acute heart attack and 2.5 million deaths occur every year due to AMI. In Mongolia Cardiovascular disease is also leading the cause of mortality and morbidity. It is dramatically increasing every year, 479.4 per 10,000 population in 2012 was increased to 848.1 per 10,000 population in 2013. Dr.B.Jerardin, Prof.Z.Lkhagvasuren and his junior L.Jargalsaikhan jointly implanted first stent inMongolia in 2010. There is rapid development in interventional treatment skills since then. Since 2000 until 2014, total of 3791 coronary angioraphy, 1841 stent implantations was performed.This study has included the patients of last 5 years. Total of 898 patients who are treated with AMI during October 2010 to October 2014 at Third State Central Hospital were analyzed. 73.7% of the patients had left coronary artery disease and 26.3% had right coronary disease. Thisfinding was same with other local researchers study (Galtsog et al. 1987, D.Narantuya et al. 2001).59.4% of the occlusions were 75-99% stenosis, 23.5% had total occlusion. 62.9% of the LAD occlusionwere stenosis of over 75%. It demonstrated majority of the cases performed were high severe lesions.This also may be demonstrating that patients are receiving treatment in their late stage of the disease. Early stage complication such as mortality, restenosis was 3.5%, complication within following one month of after stent implantation was 9-13.1%. Overall mortality rate has decreased each year, 11.9% in 2010, 7.8% in 2012, 4.6% in 2013 relatively. General achievement is now 88.1%-95.4%, which is comparable to other countries.Implementation of coronary procedures in daily practice was one of the major achievements in thecardiovascular field in Mongolia. Patients from capital city are relatively been able to receive coronaryinterventional treatment within 12 hours of onset. However, patients arriving golden standard timingis not sufficient enough as well there are still major concerns for patients living in distant rural areas.